Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis

Modern Rheumatology

Volumn 23, Issue 5, 2013, Pages 872-883

  Arai, Satoko ^a   Kurasawa, Kazuhiro ^a   Maezawa, Reika ^a   Owada, Takayoshi ^a   Okada, Harutsugu ^a   Fukuda, Takeshi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Interstitial pneumonia; KL 6; PM DM; Prognosis; SP D

Indexed keywords

CARBON MONOXIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; GLYCOPROTEIN; JO 1 ANTIBODY; PROTEIN KL 6; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG CAPACITY; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RESPIRATORY FAILURE; SURVIVAL RATE; THORAX RADIOGRAPHY; TREATMENT DURATION; VITAL CAPACITY;

ADULT; AGED; DERMATOMYOSITIS; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MUCIN-1; PROGNOSIS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84885175080     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0756-0     Document Type: Article

References (31)

1. Marie I, Hachulla E, Chérin P, Dominique S, Hatron PY, Hellot MF, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47:614-22.
2. Fathi M, Lundberg IE. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol. 2005;17:701-6.
3. Nawata Y, Kurasawa K, Takabayashi K, Miike S, Watanabe N, Hiraguri M, et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/ polymyositis: prediction and treatment with cyclosporine. J Rheumatol. 1999;26:1527-33.
4. Hirakata M, Nagai S. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol. 2000;12:501-8.
5. Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63:297-301.
6. Yamasaki Y, Yamada H, Ohkubo M, Yamasaki M, Azuma K, Ogawa H, et al. Long term survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol. 2011;38:1636-43.
7. Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK, Song YW. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford). 2005;44:1282-6.
8. Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32:1719-26.
9. Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S, et al. Clinical differences between interstitial lung disease associated with clinically amyopathicdermatomyositis and classic dermatomyositis. Chest. 2009;136:1341-7.
10. Fujisawa T, Suda T, Nakamura Y, Enomoto N, Ide K, Toyoshima M, et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol. 2005;32:58-64.
11. Kurasawa K, Nawata Y, Takabayashi K, Kumano K, Kita Y, Takiguchi Y, et al. Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis. Clin Exp Immunol. 2002;129:541-8.
12. Gono T, Kawaguchi Y, Hara M, Masuda I, Katsumata Y, Shinozaki M, et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49:1354-60.
13. Nukiwa T. The role of biomarkers in management of interstitial lung disease: implications of biomarkers derived from type II pneumocytes. In: du Bois RM, Richeldi L, editors. Interstitial lung diseases. European Respiratory Society Monograph, vol 46. 2009. p. 47-66.
14. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest. 1989;96:68-73.
15. Hermans C, Bernard A. Lung epithelium-specific proteins: characteristics and potential applications as markers. Am J Respir Crit Care Med. 1999;159:646-78.
16. Ishizaka A, Matsuda T, Albertine KH, Koh H, Tasaka S, Hasegawa N, et al. Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol. 2004;286:L1088-94.
17. Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest. 1995;108:311-5.
18. Nakajima H, Harigai M, Hara M, Hakoda M, Tokuda H, Sakai F, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol. 2000;27:1164-70.
19. Greene KE, Wright JR, Steinberg KP, Ruzinski JT, Caldwell E, Wong WB, et al. Serial changes in surfactant- associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med. 1999;160:1843-50.
20. Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino T, Abe S. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med. 1995;152:1860-6.
21. Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y, et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med. 2000;162:1109-14.
22. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344-7.
23. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46:626-36.
24. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Kuwana M. RNA helicase encoded by melanoma diff erentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60:2193-200.
25. Arakawa H, Yamada H, Kurihara Y, Nakajima Y, Takeda A, Fukushima Y, Fujioka M. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest. 2003;123:1096-103.
26. Ooi GC, Mok MY, Tsang KW, Wong Y, Khong PL, Fung PC, et al. Interstitial lung disease in systemic sclerosis. Acta Radiol. 2003;44:258-64.
27. Kubo M, Ihn H, Yamane K, Kikuchi K, Yazawa N, Soma Y, Tamaki K. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford). 2000; 39: 632-6.
28. Bandoh S, Fujita J, Ohtsuki Y, Ueda Y, Hojo S, Tokuda M, et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis. Ann Rheum Dis. 2000;59:257-62.
29. Ihn H, Asano Y, Kubo M, Yamane K, Jinnin M, Yazawa N, et al. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease. Rheumatology (Oxford). 2002;41:1268-72.
30. Ohtsuki Y, Nakanishi N, Fujita J, Yoshinouchi T, Kobayashi M, Ueda N, et al. Immunohistochemical distribution of SP-D, compared with that of SP-A and KL-6, in interstitial pneumonias. Med Mol Morphol. 2007;40:163-7.
31. Takahashi H, Shiratori M, Kanai A, Chiba H, Kuroki Y, Abe S. Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D. Respirology. 2006;11:S51-4.